Company / Cash & Equivalents
Silo Pharma, Inc. Cash & Equivalents History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$3.9M
FY2025
5-year range
$336.7K / $3.9M
FY2021-FY2025
Trend
+0.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $4M to $4M over the past 2 years.
Based on SEC 10-K filings.
$4M in FY2025 with a 5-year CAGR of +63.3%.
Improved from $4M to $4M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +63.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +63.3%, indicating consistent growth.
- In FY2025, cash & equivalents increased 0.0% year-over-year.
- Lowest cash & equivalents in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.9M | +0.0% |
| FY2024 | $3.9M | +10.8% |
| FY2023 | $3.5M | +946.8% |
| FY2020 | $336.7K | +0.0% |
| FY2019 | $336.7K | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026